

Supporting Information

Desymmetrization of Aziridine with Malononitrile using Cinchona Alkaloid Amide/Zinc(II) Catalysts

Noriyuki Shiomi,^{a,b} Mami Kuroda,^a Shuichi Nakamura*,^{a,b}

^aDepartment of Life Science and Applied Chemistry, Graduate School of Engineering,
Nagoya Institute of Technology, Gokiso, Showa-ku, Nagoya 466-8555 (Japan)


^bFrontier Research Institute for Material Science, Nagoya Institute of Technology,
Gokiso, Showa-ku, Nagoya 466-8555 (Japan)

General Methods:

All reactions were performed in oven-dried glassware under a positive pressure of argon. Solvents were transferred via syringe and were introduced into the reaction vessels through a rubber septum. All reactions were monitored by thin-layer chromatography (TLC) carried out on 0.25 mm Merck silica-gel (60-F254). The TLC plates were visualized with UV light and 7% phosphomolybdic acid or *p*-anisaldehyde in ethanol/heat. Column chromatography was carried out on a column packed with silica-gel 60N spherical neutral size 63-210 μm . The ¹H NMR (300 MHz), ¹³C NMR (75.5 MHz) spectra for solution in CDCl₃, were recorded on a Varian Gemini-300. Chemical shifts (δ) are expressed in ppm downfield from internal TMS or CHCl₃. HPLC analyses were performed on a JASCO PU-2080 Plus using 4.6 x 250 mm DAICEL CHIRALPAK column. ESI Mass spectra was recorded on a SHIMADZU LCMS-2050EV. Optical rotations were measured on a JASCO P-2200. Infrared spectra were recorded on a JASCO FT/IR-4600 spectrometer.

Optimization of reaction conditions:

Table S1. Screening of Lewis acids.^a




Entry	Metal species	Yield (%)	Ee (%) ^b
1	none	-	-
2 ^c	Et ₂ Zn	63	90
3	Zn(OAc) ₂	53	11
4	Zn(OTf) ₂	41	14
5 ^d	Zn(OTf) ₂	58	81
6 ^d	Cu(OTf) ₂	10	79
7 ^d	Ni(OTf) ₂	35	33 ^e
8 ^d	Sc(OTf) ₃	16	0

^a Reaction condition; aziridine **1** (0.1 mmol), malononitrile (1.5 equiv.), Et₂Zn (10 mol %), **3** (1 mol %) in THF (0.1 M) were used. ^b Ee was determined by HPLC analysis using a chiral column.

^c Ligand **3** (12 mol%) was used. ^d Et₃N (1.0 equiv.) was added. ^e Opposite enantiomer was obtained.

Table S2. Screening of ligands.^a




Entry	R (chiral ligand)	Time (h)	Yield (%)	Ee (%) ^b
1	H	6	74	88
2	4-CF ₃	20	45	24
3	4-Cl	24	57	61
4	4-OMe	12	71	91
5	6-F	40	60	3 ^c
6	6-Me	32	54	30 ^c
7	6-OMe	32	60	6 ^c

^a Reaction condition; aziridine **1** (0.1 mmol), malononitrile (5.0 equiv.), Et_2Zn (10 mol %), ligand (12 mol %) in THF (0.2 M) were used. ^b Ee was determined by HPLC analysis using a chiral column.

^c Opposite enantiomer was obtained.

Table S3. Screening of protecting groups.^a




Entry	Ar	Time (h)	Yield (%)	Ee (%) ^b
1		6	74	88
2		72	-	-
3		66	trace	-
4		66	19	24
5		17	69	81
6		3	84	92
7		6	88	95
8		12	82	96
9 ^c		20	89	97

^a Reaction condition; aziridine **1** (0.1 mmol), malononitrile (5.0 equiv.), Et₂Zn (10 mol%), **3** (12 mol%) in THF (0.2 M) were used. ^b Ee was determined by HPLC analysis using a chiral column.

^c At 0 °C.


General procedure for synthesis of *N*-(imidazolecarbonyl)aziridines:



A solution of 1-methylimidazole (3.16 mL, 40 mmol) in Et₂O (120 mL) was cooled to -78 °C and added *n*-BuLi (1.6 M solution in Hexane, 44 mmol) dropwise. After stirring for 1 h, CO₂ gas was bubbled to the reaction mixture, and stirred overnight. The reaction mixture was filtrated and washed with Et₂O, and dried in vacuo to afford lithium 1-methyl-1*H*-imidazole-2-carboxylate as a white solid in quantitative yield. This compound was used in the next step without further purification.

To a solution of lithium 1-methyl-1*H*-imidazole-2-carboxylate (924 mg, 7.0 mmol) in CH₃CN (10.5 mL), oxalyl chloride (3.6 mL, 42 mmol) was added dropwise at 0 °C. After stirring for 30 min at 0 °C, the reaction mixture was warmed to room temperature and stirred for 2 h. The volatile compounds were removed under reduced pressure, and the yellow crude compound was used in the next step immediately without further purification.


7-Aza-bicyclo[4.1.0]heptane (340 mg, 3.5 mmol) in CH₂Cl₂ (9.1 mL) was added Et₃N (1.9 mL, mmol) and cooled to -50 °C. 1-Methyl-1*H*-imidazole-2-carbonyl chloride hydrochloride (760 mg, 4.2 mmol) was added slowly to the reaction mixture and stirred for overnight. The mixture was added H₂O and warmed to room temperature. The organic layer was separated and water layer was extracted with CH₂Cl₂ twice. The combined organic layer was washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by flash column chromatography (Hexane/AcOEt=70/30) to afford **1b** in 58% yield as a white solid.




7-Aza-bicyclo[4.1.0]heptane (219 mg, 2.3 mmol) in CH₂Cl₂ (5.6 mL) was cooled to -20 °C and added Et₃N (1.3 mL, 9.0 mmol) followed by imidazole-2-acylchloride hydrochloride salt (453 mg, 2.7 mmol) synthesized by previous report.^{1,2} After stirring overnight, the reaction mixture was added H₂O, and warmed to room temperature. The mixture was extracted with CH₂Cl₂ three times and the combined organic layer was dried over Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by flash chromatography (Hexane/AcOEt=50/50) to afford (7-azabicyclo[4.1.0]heptan-7-yl)(1*H*-imidazol-2-yl)methanone in 85% yield as a white solid.

A solution of (7-azabicyclo[4.1.0]heptan-7-yl)(1*H*-imidazol-2-yl)methanone (279 mg, 1.5 mmol)

in DMF (4.0 mL) was cooled to 0 °C and added NaH (117 mg, 60% mineral oil suspension, 2.9 mmol). After stirring for 30 min, ethyl iodide (0.14 mL, 1.8 mmol) was added dropwise. After stirring for 6 h, the reaction mixture was added H₂O and warmed to room temperature. The reaction mixture extracted with AcOEt twice. The combined organic layer was washed with brine, dried over Na₂SO₄, and concentrated under reduced pressure. The residue was purified by flash column chromatography (Hexane/AcOEt=70/30) to afford **1c** in 40% yield as a white solid.




A solution of (7-azabicyclo[4.1.0]heptan-7-yl)(1H-imidazol-2-yl)methanone (191 mg, 1.0 mmol) and K₂CO₃ (276 mg, 1.2 mmol) in MeCN (2.5 mL) was cooled to 0 °C and added benzyl bromide (0.14 mL, 1.2 mmol) dropwise. The reaction mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was diluted with MeCN and filtrated through celite, and the volatile compounds were removed under reduced pressure. The crude product was purified by silica gel column chromatography (Hexane/AcOEt=80/20) to afford **1d** in 58% yield as a white solid.



A solution of *trans*-6-azidocyclohex-3-enol (417 mg, 3.0 mmol) in THF (15 mL) was added triphenyl phosphine (944 mg, 3.6 mmol) and refluxed for 5 h. The reaction mixture was cooled to -30 °C, and Et₃N (1.67 mL, 12 mmol) was added to the solution followed by 1-methyl-1H-imidazole-2-carbonyl chloride hydrochloride (650 mg, 3.6 mmol) in portionwise. After stirring overnight, the reaction mixture was added H₂O and warmed to room temperature. The mixture was extracted with CH₂Cl₂ three times and the combined organic layer was dried over Na₂SO₄, and concentrated under reduced pressure. The crude product was purified by flash chromatography (Hexane/AcOEt=60/40) to afford **1e** in 51% yield as a white solid.

Compound **1f**, **1h** were prepared by similar method for the preparation of **1e**.




Chopped sodium metal (322 mg, 14 mmol) was added to a solution of naphthalene (1.97 g, 15.4

mmol) in 1,2-dimethoxyethane (12 mL) and stirred at room temperature for 1 h. The reaction mixture became a dark green solution, and it was added to a solution of 6-tosyl-6-azabicyclo[3.1.0]hexane (1.66 mg, 7.0 mmol) in 1,2-dimethoxyethane (24 mL) at $-78\text{ }^{\circ}\text{C}$. After stirring for 1 h, the reaction mixture was added H_2O (0.25 mL), and stirred for 30 min at room temperature. Then, MgSO_4 was added to the reaction mixture and stirred for 15 min. The precipitate was filtrated off through celite and washed with Et_2O . After removal of Et_2O under reduced pressure, the residue was cooled to $-30\text{ }^{\circ}\text{C}$, and Et_3N (3.9 mL, 28 mmol) was added to the solution followed by 1-methyl-1*H*-imidazole-2-carbonyl chloride hydrochloride (1.52 g, 8.4 mmol) in portionwise. After stirring overnight, the reaction mixture was added H_2O and warmed to room temperature. The mixture was extracted with AcOEt three times and the combined organic layer was dried over Na_2SO_4 , and concentrated under reduced pressure. The crude product was purified by flash chromatography (Hexane/AcOEt=50/50) to afford **1g** in 38% yield as a white solid.


Compound **1i** was prepared by similar method for the preparation of **1g**.

(7-Azabicyclo[4.1.0]heptan-7-yl)(1*H*-imidazol-2-yl)methanone;




m.p. 111.8-112.4 $^{\circ}\text{C}$; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.30-1.39 (m, 2H), 1.48-1.59 (m, 2H), 1.91-1.95 (m, 2H), 2.18-2.27 (m, 2H), 2.97-2.98 (m, 2H), 7.21 (d, $J = 3.0\text{ Hz}$, 1H), 7.27 (d, $J = 3.0\text{ Hz}$, 1H), 11.5 (br, 1H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 20.0, 23.8, 37.7, 119.8, 131.2, 141.3, 170.5; **IR** (ATR) 2945, 2910, 1665, 1389, 1310, 1198, 1092, 947, 799, 697 cm^{-1} ; **HRMS** (ESI) calculated for $\text{C}_{10}\text{H}_{13}\text{N}_3\text{NaO}^+$ $[\text{M}+\text{Na}]^+$ 213.0956. found 214.0957.

(7-Azabicyclo[4.1.0]heptan-7-yl)(1-methyl-1*H*-imidazol-2-yl)methanone (1b);



m.p. 57.8-58.8 $^{\circ}\text{C}$; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.29-1.38 (m, 2H), 1.50-1.57 (m, 2H), 1.87-1.95 (m, 2H), 2.15-2.24 (m, 2H), 2.91-2.92 (m, 2H), 4.00 (s, 3H), 6.98 (d, $J = 0.9\text{ Hz}$, 1H), 7.12 (d, $J = 0.9\text{ Hz}$, 1H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 20.2, 23.9, 36.1, 37.7, 125.9, 129.1, 139.7, 171.0; **IR** (ATR) 2931, 1651, 1404, 1273, 1191, 1132, 895, 823, 776, 675 cm^{-1} ; **HRMS** (ESI) calculated for $\text{C}_{11}\text{H}_{15}\text{N}_3\text{NaO}^+$ $[\text{M}+\text{Na}]^+$ 228.1113. found 228.1116.


(7-Azabicyclo[4.1.0]heptan-7-yl)(1-Ethyl-1*H*-imidazol-2-yl)methanone (1c);




m.p. 52.0-53.0 $^{\circ}\text{C}$; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.26-1.33 (m, 2H), 1.34-1.44 (m, 3H), 1.48-1.59 (m, 2H), 1.87-1.95 (m, 2H), 2.15-2.25 (m, 2H), 2.91-2.92 (m, 2H), 4.45 (q, $J = 7.2\text{ Hz}$, 2H), 7.05 (d, $J = 0.9\text{ Hz}$, 1H), 7.13 (d, $J = 0.9\text{ Hz}$, 1H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 16.7, 20.2, 37.7, 43.6, 124.1, 129.3, 139.0, 170.8; **IR** (ATR) 2922, 1661, 1407, 1268, 1136, 894, 784, 670 cm^{-1} ; **HRMS** (ESI) calculated for

$C_{12}H_{17}N_3NaO^+$ $[M+Na]^+$ 242.1269. found 242.1269.


(1-Benzyl-1*H*-imidazol-2-yl)(7-azabicyclo[4.1.0]heptan-7-yl)methanone (1d);




(7-azabicyclo[4.1.0]hept-3-en-7-yl)(1-methyl-1*H*-imidazol-2-yl)methanone (1e);




(1-Methyl-1*H*-imidazol-2-yl)(1a,2,7,7a-tetrahydro-1*H*-naphtho[2,3-*b*]azirin-1-yl)methanone (1f);




(6-Azabicyclo[3.1.0]hexan-6-yl)(1-methyl-1*H*-imidazol-2-yl)methanone (1g);




(2,3-Dimethylaziridin-1-yl)(1-methyl-1H-imidazol-2-yl)methanone (1h);

 **m.p.** 80.0-61.0 °C; **¹H NMR** (300 MHz, CDCl₃) δ 1.41 (d, *J* = 5.4 Hz, 6H), 2.75-2.79 (m, 1H), 4.00 (s, 3H), 6.99 (s, 1H), 7.12 (s, 1H); **¹³C NMR** (75 MHz, CDCl₃) δ 12.9, 36.0, 38.1, 126.0, 129.1, 139.6, 171.2; **IR** (ATR) 3129, 3114, 2958, 1656, 1453, 1416, 1453, 1416, 1312, 1283, 1164, 903, 788, 670 cm⁻¹; **HRMS** (ESI) calculated for C₉H₁₃N₃NaO⁺ [M+Na]⁺ 202.0956. found 202.0961.


(2,3-Diethylaziridin-1-yl)(1-methyl-1H-imidazol-2-yl)methanone (1i);

 **m.p.** 71.5-72.5 °C; **¹H NMR** (300 MHz, CDCl₃) δ 1.11 (t, *J* = 7.5 Hz, 6H), 1.54-1.63 (m, 2H), 1.90-1.99 (m, 2H), 2.63-2.66 (m, 2H), 4.00 (s, 3H), 6.99 (d, *J* = 0.9 Hz, 1H), 7.11 (d, *J* = 0.9 Hz, 1H); **¹³C NMR** (75 MHz, CDCl₃) δ 11.6, 21.0, 35.9, 44.3, 125.9, 128.9, 139.5, 171.1; **IR** (ATR) 2961, 1658, 1407, 1284, 1144, 1011, 907, 788, 663 cm⁻¹; **HRMS** (ESI) calculated for C₁₁H₁₇N₃NaO⁺ [M+Na]⁺ 230.1269. found 230.1273.

(2,3-Dipropylaziridin-1-yl)(1-methyl-1H-imidazol-2-yl)methanone (1j);


 **m.p.** 80.5-81.5 °C; **¹H NMR** (300 MHz, CDCl₃) δ 0.96-1.03 (m, 6H), 1.50-1.62 (m, 6H), 1.83-1.88 (m, 2H), 2.67-2.69 (m, 2H), 3.99 (s, 3H), 6.99 (s, 1H), 7.12 (s, 1H); **¹³C NMR** (75 MHz, CDCl₃) δ 14.1, 20.7, 29.9, 36.0, 42.9, 126.0, 129.0, 139.6, 171.3; **IR** (ATR) 2953, 1657, 1410, 1285, 1153, 914, 794, 663 cm⁻¹; **HRMS** (ESI) calculated for C₁₃H₂₁N₃NaO⁺ [M+Na]⁺ 258.1582. found 258.1587.

General procedure for the enantioselective desymmetrization of aziridines with malononitrile:




Ligand **3a** (4.8 mg, 0.012 mmol) and Et₂Zn (1.11M solution in toluene, 9.0 μL, 0.01 mmol) was dissolved in THF (0.5 mL) and stirred at room temperature for 30 min. Aziridine **1b** (20.5 mg, 0.1 mmol) was added to a solution and cooled to 0 °C, then malononitrile (33.1 mg, 0.5 mmol) was added. After stirring for 20 h, the reaction mixture was diluted with AcOEt and filtered through the celite pad, and the volatile compounds were removed under reduced pressure. The crude product was purified by silica gel column chromatography (Hexane/AcOEt=50/50) to give (1*R*,2*S*)-**2b** in 89% yield 97% ee) as a white solid. (1*S*,2*R*)-**2b** can be synthesised by using ligand **3b** instead of **3a** in 74% yield 94% ee).

***N*-(2-(1*R*,2*S*)-2-(Dicyanomethyl)cyclohexyl)picolinamide (2a);**



[α]_D²⁵ -33.2 (*c* 0.59, CHCl₃, 88% ee); **m.p.** 109.0-111.0 °C; **¹H NMR** (300 MHz, CDCl₃) δ 1.35-1.72 (m, 4H), 1.89-1.97 (m, 2H), 2.06-2.16 (m, 2H), 2.23-2.27 (m, 1H), 3.92-4.04 (m, 1H), 4.09-4.10 (m, 1H); **¹³C NMR** (75 MHz, CDCl₃) δ 24.7, 24.8, 26.6, 28.3, 33.0, 45.9, 50.1, 111.4, 113.0, 122.7, 126.9, 137.8, 148.2, 149.0, 164.9; **IR** (ATR) 3339, 2925, 2362, 1737, 1655, 1520, 1365, 1217, 729 cm⁻¹; **HRMS** (ESI) calculated for C₁₅H₁₆N₄NaO⁺ [M+Na]⁺ 291.1222. found 291.1230; **HPLC** (DAICEL CHIRALPAK IC-3, Hexane:*i*PrOH = 70:30, 1.0 mL/min, 215 nm) *t*_(1*S*,2*R*) = 15.6, *t*_(1*R*,2*S*) = 20.2 min.


***N*-(2-(1*S*,2*R*)-2-(Dicyanomethyl)cyclohexyl)-1-methyl-1*H*-imidazole-2-carboxamide (2b);**



(1*S*,2*R*)-**2b**: [α]_D²⁵ -13.6 (*c* 0.72, CHCl₃, 97% ee); (1*R*,2*S*)-**2b**: [α]_D²⁵ +34.5 (*c* 0.59, CHCl₃, 94% ee); **m.p.** 151.0-152.0 °C; **¹H NMR** (300 MHz, CDCl₃) δ 1.29-1.52 (m, 3H), 1.54-1.68 (m, 1H), 1.87-1.94 (m, 2H), 1.98-2.12 (m, 2H), 2.21-2.25 (m, 1H), 3.84-3.96 (m, 1H), 4.06 (s, 3H), 4.11 (d, *J* = 3.3 Hz, 1H), 7.01 (s, 2H), 7.21 (s, 1H); **¹³C NMR** (75 MHz, CDCl₃) δ 24.6, 24.8, 26.4, 28.1, 33.0, 35.8, 45.5, 49.5, 111.5, 112.9, 126.1, 127.8, 138.4, 159.5; **IR** (ATR) 3288, 2925, 2360, 1650, 1550, 1270, 1155, 825, 748, 658 cm⁻¹; **HRMS** (ESI) calculated for C₁₄H₁₇N₅NaO⁺ [M+Na]⁺ 294.1331. found 294.1330; **HPLC** (DAICEL CHIRALPAK ID-3,

Hexane:*i*PrOH = 80:20, 1.0 mL/min, 215 nm) $t_{(1S,2R)} = 12.9$, $t_{(1R,2S)} = 20.0$ min.


***N*-((1*R*,2*S*)-2-(Dicyanomethyl)cyclohexyl)-1-ethyl-1*H*-imidazole-2-carboxamide (2c);**



$[\alpha]_D^{25} -24.2$ (*c* 0.81, CHCl₃, 95% ee); ¹H NMR (300 MHz, CDCl₃) δ 1.31-1.54 (m, 6H), 1.57-1.67 (m, 1H), 1.87-1.94 (m, 2H), 1.99-2.11 (m, 2H), 2.20-2.25 (m, 1H), 3.84-3.94 (m, 1H), 4.11 (d, *J* = 3.6 Hz, 1H), 4.44-4.61 (m, 2H), 7.01 (s, 1H), 7.07 (s, 1H), 7.35 (d, *J* = 9.0 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 16.7, 24.7, 24.8, 26.5, 28.2, 33.1, 43.5, 45.7, 49.6, 111.4, 112.9, 124.3, 128.0, 137.7, 159.3; IR (ATR) 3366, 2936, 2360, 1662, 1534, 1497, 1263, 1155, 765 cm⁻¹;

HRMS (ESI) calculated for C₁₅H₁₉N₅NaO⁺ [M+Na]⁺ 308.1487. found 308.1493; **HPLC** (DAICEL CHIRALPAK IG, Hexane:*i*PrOH = 90:10, 1.0 mL/min, 215 nm) $t_{(1S,2R)} = 17.7$, $t_{(1R,2S)} = 20.5$ min.


1-Benzyl-*N*-((1*R*,2*S*)-2-(dicyanomethyl)cyclohexyl)-1*H*-imidazole-2-carboxamide (2d);



$[\alpha]_D^{25} -23.6$ (*c* 0.85, CHCl₃, 96% ee); **m.p.** 135.0-136.0 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.26-1.45 (m, 3H), 1.51-1.60 (m, 1H), 1.86-2.02 (m, 3H), 2.05-2.07 (m, 1H), 2.18-2.22 (m, 1H), 3.86-3.91 (m, 2H), 5.64-5.75 (m, 2H), 7.03 (s, 1H), 7.04 (s, 1H), 7.21-7.24 (m, 2H), 7.28-7.39 (m, 4H); ¹³C NMR (75 MHz, CDCl₃) δ 24.7, 24.8, 26.3, 28.1, 32.9, 45.8, 49.5, 51.6, 111.4, 112.9, 125.1, 127.9, 128.2, 128.3, 129.0, 136.6, 138.1, 159.4; IR (ATR) 3726, 3702, 3624,

3603, 2364, 2341, 2309, 1655, 1529, 1496, 1464, 784, 731, 669 cm⁻¹; **HRMS** (ESI) calculated for C₂₀H₂₁N₅NaO⁺ [M+Na]⁺ 370.1644. found 370.1653; **HPLC** (DAICEL CHIRALPAK IC-3, Hexane:*i*PrOH = 90:10, 1.0 mL/min, 215 nm) $t_{(1S,2R)} = 17.4$, $t_{(1R,2S)} = 20.1$ min.


***N*-((1*R*,6*S*)-6-(Dicyanomethyl)cyclohex-3-en-1-yl)-1-methyl-1*H*-imidazole-2-carboxamide (2e);**



$[\alpha]_D^{25} -40.6$ (*c* 0.58, CHCl₃, 94% ee); ¹H NMR (300 MHz, CDCl₃) δ 2.29-2.67 (m, 5H), 4.06 (s, 3H), 4.14 (d, *J* = 4.5 Hz, 1H), 4.19-4.24 (m, 1H), 5.73 (s, 2H), 7.01 (s, 2H), 7.41 (d, *J* = 8.7 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 25.8, 28.1, 31.6, 35.9, 40.7, 46.8, 111.4, 112.5, 124.2, 125.0, 126.3, 127.9, 138.3, 159.5; IR (ATR) 3726, 3381, 3033, 2844, 1721, 1659, 1536, 1498, 1473, 1269, 1154, 734, 679 cm⁻¹; **HRMS** (ESI) calculated for C₁₄H₁₅N₅NaO⁺ [M+Na]⁺ 292.1174.

found 292.1174; **HPLC** (DAICEL CHIRALPAK ID-3, Hexane:*i*PrOH = 80:20, 1.0 mL/min, 209 nm) $t_{(1S,6R)} = 17.2$, $t_{(1R,6S)} = 20.6$ min.


***N*-((2*R*,3*S*)-3-(Dicyanomethyl)-1,2,3,4-tetrahydronaphthalen-2-yl)-1-methyl-1*H*-imidazole-2-carboxamide (2f);**



$[\alpha]_D^{25}$ -33.1 (*c* 0.27, CHCl₃, 73% ee); ¹H NMR (300 MHz, CDCl₃) δ 2.64-2.71 (m, 1H), 2.98-3.37 (m, 4H), 4.07 (s, 3H), 4.33 (d, *J* = 4.8 Hz, 1H), 4.37-4.40 (m, 1H), 7.02 (s, 2H), 7.11-7.12 (m, 1H), 7.20-7.26 (m, 3H), 7.49 (d, *J* = 8.4 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 26.2, 31.8, 35.3, 35.9, 42.0, 47.8, 111.3, 112.5, 126.3, 127.2, 128.0, 128.8, 132.4, 133.0, 138.3, 159.7; IR (ATR) 3362, 2929, 2359, 2254, 1665, 1536, 1496,

1474, 1154, 909, 730 cm⁻¹; HRMS (ESI) calculated for C₁₈H₁₇N₅NaO⁺ [M+Na]⁺ 342.1331. found 342.1318; HPLC (DAICEL CHIRALPAK IC-3, Hexane:*i*PrOH = 90:10, 1.0 mL/min, 209 nm) *t*_(2*S*,3*R*) = 26.8, *t*_(2*R*,3*S*) = 30.0 min.


***N*-((1*R*,2*S*)-2-(Dicyanomethyl)cyclopentyl)-1-methyl-1*H*-imidazole-2-carboxamide (2g);**



$[\alpha]_D^{25}$ -13.3 (*c* 0.47, CHCl₃, 95% ee); m.p. 99.0-100.0 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.69-1.92 (m, 4H), 2.17-2.25 (m, 2H), 2.38-2.42 (m, 1H), 4.02 (s, 3H), 4.15-4.20 (m, 1H), 4.63 (d, *J* = 4.2 Hz, 1H), 6.98 (s, 1H), 6.98 (s, 1H), 7.47 (br, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 22.8, 26.5, 28.5, 32.4, 35.7, 48.2, 54.0, 112.2, 112.9, 126.0, 127.9, 138.3, 160.1; IR (ATR) 3390, 2969, 2360, 1735, 1655, 1506, 1281, 1091, 912, 731 cm⁻¹; HRMS (ESI) calculated for

C₁₃H₁₅N₅NaO⁺ [M+Na]⁺ 280.1174. found 280.1173; HPLC (DAICEL CHIRALPAK IC-3, Hexane:*i*PrOH = 80:20, 1.0 mL/min, 215 nm) *t*_(1*S*,2*R*) = 14.5, *t*_(1*R*,2*S*) = 16.5 min.


(4*S*,5*R*)-2-amino-4,5-dimethyl-1-(1-methyl-1*H*-imidazole-2-carbonyl)-4,5-dihydro-1*H*-pyrrole-3-carbonitrile (2h);



$[\alpha]_D^{25}$ +56.0 (*c* 0.51, CHCl₃, 90% ee); m.p. 126.5-127.5 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.17-1.22 (m, 6H), 2.48-2.52 (m, 1H), 3.93 (s, 3H), 5.21 (br, 1H), 6.39 (br, 2H), 7.02 (s, 1H), 7.11 (s, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 20.8, 21.7, 36.3, 40.9, 64.4, 66.4, 119.6, 125.9, 128.3, 138.7, 156.3, 160.3; IR (ATR) 3400, 2962, 2179, 1644, 1551, 1404, 1167, 987, 780, 658 cm⁻¹; HRMS (ESI) calculated for C₁₂H₁₅N₅NaO⁺ [M+Na]⁺ 268.1174. found 268.1174;


HPLC (DAICEL CHIRALPAK IC-3, Hexane:*i*PrOH = 80:20, 1.0 mL/min, 215 nm) *t*_(4*R*,5*S*) = 17.8, *t*_(4*S*,5*R*) = 22.6 min.

(4*S*,5*R*)-2-amino-4,5-diethyl-1-(1-methyl-1*H*-imidazole-2-carbonyl)-4,5-dihydro-1*H*-pyrrole-3-carbonitrile (2i);




$[\alpha]_{\text{D}}^{25} +46.7$ (*c* 0.63, CHCl₃, 94% ee); **¹H NMR** (300 MHz, CDCl₃) δ 0.83 (t, *J* = 7.2 Hz, 3H), 1.00 (t, *J* = 7.2 Hz, 3H), 1.47-1.67 (m, 4H), 2.45-2.49 (m, 1H), 3.92 (s, 3H), 5.25 (br, 1H), 6.41 (br, 2H), 7.00 (s, 1H), 7.10 (s, 1H); **¹³C NMR** (75 MHz, CDCl₃) δ 8.9, 10.7, 28.5, 36.2, 44.4, 64.7, 66.8, 120.0, 125.8, 128.3, 138.8, 157.4, 160.3; **IR** (ATR) 3726, 3700, 2970, 2366, 1468, 1434, 1376, 1334, 1158, 806, 754 cm⁻¹; **HRMS** (ESI) calculated for C₁₄H₁₉N₅NaO⁺ [M+Na]⁺ 396.1487. found 296.1491; **HPLC** (DAICEL CHIRALPAK ID-3, Hexane:*i*PrOH = 90:10, 1.0 mL/min, 215 nm) *t*_(4*S*,5*R*) = 22.2, *t*_(4*R*,5*S*) = 25.1 min.

(4*S*,5*R*)-2-amino-1-(1-methyl-1*H*-imidazole-2-carbonyl)-4,5-dipropyl-4,5-dihydro-1*H*-pyrrole-3-carbonitrile (2j);



$[\alpha]_{\text{D}}^{25} +15.9$ (*c* 0.63, CHCl₃, 94% ee); **m.p.** 119.0-120.0 °C; **¹H NMR** (300 MHz, CDCl₃) δ 0.82 (t, *J* = 6.6 Hz, 3H), 0.90-1.00 (m, 3H), 1.25-1.27 (m, 3H), 1.37-1.62 (m, 5H), 2.49-2.53 (m, 1H), 3.92 (s, 3H), 5.34 (br, 1H), 6.42 (br, 2H), 7.01 (d, *J* = 0.6 Hz, 1H), 7.10 (d, *J* = 0.6 Hz, 1H); **¹³C NMR** (75 MHz, CDCl₃) δ 14.0, 14.2, 17.8, 19.6, 36.1, 37.6, 38.1, 43.2, 64.8, 66.1, 120.1, 125.7, 128.2, 138.8, 157.3, 160.4; **IR** (ATR) 3400, 2959, 2178, 1655, 1650, 1557, 1411, 1143, 771 cm⁻¹; **HRMS** (ESI) calculated for C₁₆H₂₃N₅NaO⁺ [M+Na]⁺ 324.1800. found 324.1797; **HPLC** (DAICEL CHIRALPAK IC-3, Hexane:*i*PrOH = 90:10, 1.0 mL/min, 215 nm) *t*_(4*R*,5*S*) = 28.4, *t*_(4*S*,5*R*) = 36.1 min.

Transformation of **2b** to various optically active compounds:




A solution of **2b** (97% ee, 85.7 mg, 0.32 mmol) in MeOH (6.3 mL) was cooled to -20 °C and *m*-CPBA (141 mg, 0.63 mmol) was added to the solution followed by Cs₂CO₃ (116 mg, 0.33 mmol). After stirring for 30 min, the reaction mixture was diluted with H₂O and warmed to room temperature, and extracted with CH₂Cl₂ three times. The combined organic layer was dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography (Et₂O/Hexane=95/5) to afford **4** in 67% yield (97% ee) as a colorless oil.

To a solution of **4** (97% ee, 21.6 mg, 0.08 mmol) and 4-dimethylaminopyridine (19.5 mg, 0.16 mmol) in THF (0.32 mL), di-*tert*-butyl dicarbonate (150 μL, 0.64 mmol) was added and refluxed for 14 h. The reaction mixture was cooled to room temperature and diluted with H₂O, and extracted with AcOEt three times. The combined organic layer was dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography (Hexane/AcOEt=60/40) to afford *N*-Boc-β-aminoester in 79% yield (96% ee) as a colorless solid.

N-Boc-β-aminoester (96% ee, 24.6 mg, 0.067 mmol) was dissolved in MeOH (0.33 mL) and added NaOMe (4.0 mg, 0.074 mmol). After stirring for 24 h at room temperature, the reaction was quenched with HCl aq. (1.0 M, 0.6 mL), and the volatile was removed under reduced pressure. The residue was added H₂O and extracted with AcOEt three times. The combined organic layer was dried over Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash column chromatography (Hexane/AcOEt=80/20) to afford **5** in 92% yield (96% ee) as a white solid.


Methyl (1*R*,2*R*)-2-(1-methyl-1*H*-imidazole-2-carboxamido)cyclohexane-1-carboxylate (**4**);



[α]_D²⁵ -28.1 (*c* 1.06, CHCl₃, 98% ee); ¹H NMR (300 MHz, CDCl₃) δ 1.23-1.46 (m, 3H), 1.62-1.78 (m, 3H), 1.96-2.01 (m, 1H), 2.06-2.11 (m, 1H), 2.43 (dt, *J* = 3.6, 11.1 Hz, 1H), 3.63 (s, 3H), 4.03 (s, 3H), 4.06-4.16 (m, 1H), 6.94 (s, 1H), 6.98 (s, 1H), 7.34 (d, *J* = 8.7 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 24.5, 24.6, 28.7, 32.6, 35.7, 49.3, 49.5, 51.9, 125.5, 127.5, 139.0, 158.5, 174.4;


IR (ATR) 3377, 2933, 1733, 1662, 1540, 1266, 1173, 1020, 733 cm⁻¹; HRMS (ESI) calculated for C₁₃H₁₉N₃NaO₃⁺ [M+Na]⁺ 288.1324. found 288.1337; HPLC (DAICEL CHIRALPAK IC-3, Hexane:*i*PrOH = 70:30, 1.0 mL/min, 215 nm) *t*_(1*R*,2*R*) = 10.6, *t*_(1*S*,2*S*) = 17.3 min.

**Methyl (1*R*,2*R*)-2-(*N*-(*tert*-butoxycarbonyl)-1-methyl-1*H*-imidazole-2-carboxamido)
Cyclohexane-1-carboxylate;**




$[\alpha]_D^{25}$ -23.3 (c 0.95, CHCl_3 , 98% ee); **m.p.** 89.5-90.5 °C; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.18-1.57 (m, 3H), 1.24 (s, 9H), 1.73-2.08 (m, 5H), 3.33 (dt, J = 3.6, 11.9 Hz, 1H), 3.62 (s, 3H), 3.84 (s, 3H), 4.47 (dt, J = 3.6, 11.9 Hz, 1H), 6.94 (s, 1H), 7.03 (s, 1H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 24.8, 25.7, 27.6, 29.2, 30.2, 34.3, 46.8, 51.8, 57.6, 82.7, 124.2, 128.3, 142.1, 153.2, 163.8, 174.8; **IR** (ATR) 2947, 1731, 1669, 1421, 1315, 1233, 1106, 768, 660 cm^{-1} ; **HRMS** (ESI) calculated for $\text{C}_{18}\text{H}_{27}\text{N}_3\text{NaO}_5^+$ $[\text{M}+\text{Na}]^+$ 388.1848. found 388.1848; **HPLC** (DAICEL CHIRALPAK ID-3, Hexane:*i*PrOH = 80:20, 1.0 mL/min, 215 nm) $t_{(1*R*,2*R*)}$ = 9.8, $t_{(1*S*,2*S*)}$ = 12.7 min.

Methyl (1*R*,2*R*)-2-((*tert*-butoxycarbonyl)amino)cyclohexane-1-carboxylate (5**);³**





$[\alpha]_D^{25}$ -5.8 (c 0.73, CHCl_3 , 96% ee); $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.12-1.26 (m, 2H), 1.31-1.48 (m, 1H), 1.42 (s, 9H), 1.54-1.74 (m, 3H), 1.89-1.93 (m, 1H), 2.01-2.06 (m, 1H), 2.23 (dt, J = 3.3 Hz, 11.1 Hz, 1H), 3.62-3.63 (m, 1H), 3.67 (s, 3H), 4.50 (br, 1H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 24.5, 24.9, 28.5, 28.6, 33.2, 50.4, 51.4, 51.9, 79.3, 155.1, 174.6; **HRMS** (ESI) calculated for $\text{C}_{13}\text{H}_{23}\text{NnaO}_4^+$ $[\text{M}+\text{Na}]^+$ 280.1525. found 280.1520.



In order to determine the enantiomeric excess, we replaced the Boc group for **5** to Cbz group. **5** (96% ee, 9.0 mg, 0.035 mmol) was dissolved in MeOH (60 μL) and added hydrogen chloride (4 M in 1,4-dioxane, 530 μL). After stirring for 1 h at room temperature, the solution was removed under reduced pressure and the residue was suspended in CH_2Cl_2 (0.85 mL). The solution was cooled to 0 °C and added Et_3N (19.5 μL , 0.14 mmol) followed by benzyl chloroformate (5.9 μL , 0.042 mmol). After stirring overnight at room temperature, sat. NaHCO_3 aq. was added to the reaction mixture and extracted with CH_2Cl_2 three times. The combined organic layer was dried over Na_2SO_4 and concentrated under reduced pressure. The crude product was purified by flash column chromatography (Benzene/AcOEt=90/10) to afford *N*-Cbz- β -aminoester in 56% yield (97% ee) as a colorless oil.


Methyl (1*R*,2*R*)-2-(((benzyloxy)carbonyl)amino)cyclohexane-1-carboxylate;³


 $[\alpha]_D^{25} -10.6$ (*c* 0.27, CHCl₃, 97% ee); ¹H NMR (300 MHz, CDCl₃) δ 1.16-1.25 (m, 2H), 1.32-1.41 (m, 1H), 1.58-1.76 (m, 3H), 1.89-1.96 (m, 1H), 2.05-2.08 (m, 1H), 2.23-2.30 (m, 1H), 3.62 (s, 3H), 3.68-3.76 (m, 1H), 4.71 (m, 1H), 5.07 (s, 2H), 7.29-7.38 (m, 5H); ¹³C NMR (75 MHz, CDCl₃) δ 24.4, 24.6, 28.6, 32.9, 49.8, 51.8, 66.6, 128.0, 128.5, 136.6, 155.4, 174.4; HRMS (ESI) calculated for C₁₆H₂₁NaNO₄⁺ [M+Na]⁺ 314.1368. found 314.1375.



Compound **6** was synthesized by modified previous method.⁴ To a solution of **2b** (98% ee, 27.1 mg, 0.1 mmol) and K₂CO₃ (27.6 mg, 0.2 mmol) in CH₃CN (1.0 mL), benzylamine (22.0 μL, 0.2 mmol) was added. The reaction mixture was stirred for 24 h under an oxygen atmosphere (balloon). The reaction mixture was diluted with CHCl₃ and filtrated through celite, and the volatile compounds were removed under reduced pressure. The crude product was purified by flash column chromatography (Hexane/AcOEt=20/80) to afford **6** in 91% yield (99% ee) as a colorless solid.


***N*-((1*R*,2*R*)-2-(Benzylcarbonyl)cyclohexyl)-1-methyl-1*H*-imidazole-2-carboxamide (**6**);**

 $[\alpha]_D^{25} -16.9$ (*c* 0.97, CHCl₃, 99% ee); **m.p.** 222.0-223.0 °C; ¹H NMR (300 MHz, CDCl₃) δ 1.26-1.49 (m, 3H), 1.52-1.65 (m, 1H), 1.78-1.81 (m, 2H), 2.00-2.11 (m, 2H), 2.32-2.44 (m, 2H), 3.79 (s, 3H), 4.03-4.10 (m, 1H), 4.31-4.47 (m, 2H), 6.57 (s, 1H), 6.92 (s, 1H), 6.98 (s, 1H), 7.04-7.13 (m, 5H), 7.51 (d, *J* = 9.6 Hz, 1H); ¹³C NMR (75 MHz, CDCl₃) δ 25.1, 25.2, 30.4, 33.1, 35.6, 43.4, 49.6, 52.0, 125.6, 127.1, 127.3, 127.6, 128.3, 138.5, 138.8, 158.9, 173.7; IR (ATR) 3730, 3303, 2933, 2855, 2347, 1640, 1546, 1470, 1270, 743, 656 cm⁻¹; HRMS (ESI) calculated for C₁₉H₂₄N₄NaO₂⁺ [M+Na]⁺ 363.1797. found 363.1800.; HPLC (DAICEL CHIRALPAK ID-3, Hexane:*i*PrOH = 70:30, 1.0 mL/min, 215 nm) *t*_(1*S*,2*R*) = 46.8, *t*_(1*R*,2*S*) = 53.8 min.



A solution of **2b** (98% ee, 27.1 mg, 0.1 mmol) in MeOH (0.7 mL) was cooled to 0 °C and added *tert-tert*-butyl dicarbonate (150 μL , 0.64 mmol) in MeOH (0.3 mL). Nickel chloride hexahydrate (71.3 mg, 0.3 mmol) was added to the reaction mixture, followed by sodium borohydride (53 mg, 1.4 mmol) was added at once. After stirring for 30 min at 0 °C, the reaction mixture was warmed to r.t. and stirred for 24 h. Diethylenetriamine (71 μL , 0.66 mmol) was added to the reaction mixture and stirred for 1 h. The mixture was diluted with AcOEt and washed with sat. NaHCO_3 aq., and dried over Na_2SO_4 . The volatile compounds were removed under reduced pressure and the residue was purified by flash column chromatography (Hexane/Acetone=80/20) to afford **7** in 59% yield (98% ee) as a colorless solid.


Di-*tert*-Butyl (2-((1*S*,2*R*)-2-(1-methyl-1*H*-imidazole-2-carboxamido)cyclohexyl)propane-1,3-diyl)dicarbamate (7);




$[\alpha]_{\text{D}}^{25} +7.1$ (c 0.86, CHCl_3 , 98% ee); **m.p.** 159.0-160.0 °C; $^1\text{H NMR}$ (300 MHz, CDCl_3) δ 1.11-1.26 (m, 3H), 1.29-1.42 (m, 20H), 1.75-1.80 (m, 4H), 1.98-2.05 (m, 1H), 3.05-3.25 (m, 4H), 3.88-3.93 (m 1H), 4.06 (s, 3H), 5.29-5.36 (m, 2H), 6.97 (s, 1H), 6.99 (s, 1H), 7.30 (br 1H); $^{13}\text{C NMR}$ (75 MHz, CDCl_3) δ 25.2, 25.4, 26.0, 28.5, 28.6, 33.7, 35.8, 39.5, 40.2, 41.9, 44.4, 49.5, 79.1, 125.7, 127.7, 159.2; **IR** (ATR) 3331, 2933, 1706, 1650, 1514, 1363, 1252, 1157, 720 cm^{-1} ; **HRMS** (ESI) calculated for $\text{C}_{24}\text{H}_{41}\text{N}_5\text{NaO}_5^+$ $[\text{M}+\text{Na}]^+$ 502.3005. found 502.2996; **HPLC** (DAICEL CHIRALPAK IG, Hexane:*i*PrOH = 80:20, 1.0 mL/min, 215 nm) $t_{(1*S*,2*R*)}$ = 16.8, $t_{(1*R*,2*S*)}$ = 25.8 min.

ESI-Mass spectroscopic analysis:


In order to clarify the assumed reaction mechanism, we investigated the ESI-Mass spectroscopic analysis of complex **C** (aziridine **1b** (0.1 mmol), malononitrile (5.0 equiv.), Et₂Zn (10 mol %), **3a** (12 mol %) in THF (0.2 M), cation mode).




Calculated for [(complex C) - (CN)₂CH]⁺ 666.2



Expanding spectra for [(complex C) - (CN)₂CH]⁺









Simulated mass spectra








References




- 1) E. Galeazzi, A. GuzmBn, J. L. Navaz, *J. Org. Chem.*, 1995, **60**, 1990.
- 2) B. Lassalle-Kaiser, R. Guillot, J. Sainton, M.-F. Charlot, A. Aukauloo, *Chem. Eur. J.*, 2008, **14**, 4307.
- 3) D. H. Appella, P. R. LePlae, T. L. Raguse, S. H. Gellman, *J. Org. Chem.*, 2000, **65**, 4766.
- 4) J. Li, M. J. Lear, Y. Hayashi, *Angew. Chem. Int. Ed.*, 2016, **55**, 9060.





















































































































racemic-**2a**



(1*R*,2*S*)-**2a**




racemic-**2a**


Peak	tR (min)	Area (%)
1	17.5	49.4
2	23.6	50.6

(1*R*,2*S*)-**2a**


Peak	tR (min)	Area (%)
1	17.7	6.2
2	23.6	93.8




racemic-**2b**



(1*R*,2*S*)-**2b**



(1*S*,2*R*)-2b



racemic-2b


Peak	tR (min)	Area (%)
1	14.0	49.9
2	23.1	50.1

(1*R*,2*S*)-2b


Peak	tR (min)	Area (%)
1	14.0	49.9
2	23.1	50.1

(1*S*,2*R*)-2b


Peak	tR (min)	Area (%)
1	11.7	97.0
2	18.6	3.0



racemic-**2c**



(1*R*,2*S*)-**2c**




racemic-**2c**


Peak	tR (min)	Area (%)
1	17.2	50.3
2	20.1	49.7

(1*R*,2*S*)-**2c**


Peak	tR (min)	Area (%)
1	17.7	2.3
2	20.5	97.7



racemic-**2d**



(1*R*,2*S*)-**2d**




racemic-**2d**


Peak	tR (min)	Area (%)
1	16.1	50.1
2	18.5	49.9

(1*R*,2*S*)-**2d**


Peak	tR (min)	Area (%)
1	17.4	1.8
2	20.1	98.2



racemic-**2e**



(1*R*,6*S*)-**2e**




racemic-**2e**


Peak	tR (min)	Area (%)
1	17.6	50.0
2	21.6	50.0

(1*R*,6*S*)-**2e**


Peak	tR (min)	Area (%)
1	17.2	3.1
2	20.6	96.9



racemic-**2f**



(*2R,3S*)-**2f**




racemic-**2f**


Peak	tR (min)	Area (%)
1	27.0	50.2
2	30.7	49.8

(*2R,3S*)-**2f**


Peak	tR (min)	Area (%)
1	28.1	13.6
2	31.2	86.4



racemic-**2g**



(1*R*,2*S*)-**2g**




racemic-**2g**


Peak	tR (min)	Area (%)
1	13.3	50.1
2	14.7	49.9

(1*R*,2*S*)-**2g**


Peak	tR (min)	Area (%)
1	14.5	97.4
2	16.5	2.6



racemic-**2h**



(4*S*,5*R*)-**2h**




racemic-**2h**


Peak	tR (min)	Area (%)
1	16.9	50.1
2	21.4	49.9

(4*S*,5*R*)-**2h**


Peak	tR (min)	Area (%)
1	17.8	5.2
2	22.6	94.8



racemic-**2i**



(*4S,5R*)-**2i**




racemic-**2i**


Peak	tR (min)	Area (%)
1	22.2	50.2
2	24.1	49.8

(*4S,5R*)-**2i**


Peak	tR (min)	Area (%)
1	22.2	96.9
2	25.1	3.1



racemic-**2j**



(4*S*,5*R*)-**2j**




racemic-**2j**


Peak	tR (min)	Area (%)
1	26.1	48.9
2	33.4	50.1

(4*S*,5*R*)-**2j**


Peak	tR (min)	Area (%)
1	28.4	2.8
2	36.1	97.2



racemic-4



(1*R*,2*R*)-4




racemic-4


Peak	tR (min)	Area (%)
1	12.3	49.9
2	21.3	50.1

(1*R*,2*R*)-4


Peak	tR (min)	Area (%)
1	10.6	98.5
2	17.3	1.5



racemic



(1*R*,2*R*)




racemic-4


Peak	tR (min)	Area (%)
1	9.8	50.2
2	12.6	49.8

(1*R*,2*R*)-4


Peak	tR (min)	Area (%)
1	9.8	98.1
2	12.7	1.9



racemic



(1*R*,2*R*)




racemic


Peak	tR (min)	Area (%)
1	43.2	50.5
2	46.1	49.5

(1*R*,2*R*)


Peak	tR (min)	Area (%)
1	42.6	98.6
2	45.9	1.4



racemic-**6**



(1*R*,2*R*)-**6**




racemic-**6**


Peak	tR (min)	Area (%)
1	46.1	50.0
2	54.4	50.0

(1*R*,2*R*)-**6**


Peak	tR (min)	Area (%)
1	46.8	0.7
2	53.8	99.3



racemic-7



(1*S*,2*R*)-7



racemic-7

Peak	tR (min)	Area (%)
1	16.6	50.0
2	24.3	50.0

(1*S*,2*R*)-7

Peak	tR (min)	Area (%)
1	16.2	99.3
2	22.9	0.7